View More Recent Stories

Feb 5, 2025 05:05AM JMP Securities Reiterates Market Outperform Rating on Solid Biosciences (SLDB)
Jan 21, 2025 08:31AM Solid Biosciences (SLDB) Receives FDA Fast Track Designation for SGT-212
Jan 15, 2025 04:06PM Solid Biosciences (SLDB) Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
Jan 8, 2025 06:05AM Truist Securities Starts Solid Biosciences (SLDB) at Buy
Jan 7, 2025 04:15PM Solid Biosciences (SLDB) Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Dec 23, 2024 04:06PM Solid Biosciences (SLDB) Added to the Nasdaq Biotechnology Index
Dec 10, 2024 03:19AM JMP Securities Starts Solid Biosciences (SLDB) at Market Outperform
Dec 4, 2024 08:02AM Solid Biosciences (SLDB) Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Nov 7, 2024 04:55PM Solid Biosciences (SLDB) Misses Q3 EPS by 79c
Aug 13, 2024 04:23PM Solid Biosciences (SLDB) Reports Q1 Loss of $0.61/sh
Jul 15, 2024 03:03AM JPMorgan Upgrades Solid Biosciences (SLDB) to Overweight
Jun 13, 2024 07:59AM Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
View More Recent Stories